The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Abstract
BACKGROUND: Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. METHODS: Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. RESULTS: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). CONCLUSIONS: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Cited by
Atkins, H. L., Bowman, M., Allan, D., Anstee, G., Arnold, D. L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30169-6 · Cited by 325
Burt, R. K., Balabanov, R., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., Fagius, J., Rose, J., Nelson, F., Barreira, A. A., et al. (2019) · JAMA · doi:10.1001/jama.2018.18743 · Cited by 313
Self-citationAutologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Muraro, P. A., Martin, R., Mancardi, G. L., Nicholas, R., Sormani, M. P., & Saccardi, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.81 · Cited by 304
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Muraro, P. A., Pasquini, M., Atkins, H. L., Bowen, J. D., Farge, D., Fassas, A., Freedman, M. S., Georges, G. E., Gualandi, F., Hamerschlak, N., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5867 · Cited by 275
Metadata
- Authors
- Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., Uggla, B., Lenhoff, S., Johansson, J.-E., Isaksson, C., Hägglund, H., Carlson, K., & Fagius, J.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2014-02-19
- Volume
- 85
- Issue
- 10
- Pages
- 1116-1121
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2165405170
- Cited by
- 166
- References
- 1
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. https://app.cochat.ai/papers/10.1136/jnnp-2013-307207
- The paper
- Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., Uggla, B., Lenhoff, S., Johansson, J.-E., Isaksson, C., Hägglund, H., Carlson, K., & Fagius, J. (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2013-307207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.